History
The compound LY 146032 was discovered by researchers at Eli Lilly and Company in the late 1980s.
LY 146032 showed promise in Phase I/II clinical trials for treatment of infection caused by Gram-positive organisms. Lilly ceased development because high dose therapy was associated with adverse effects on skeletal muscle, including myalgia and potential myositis. The rights to LY 146032 were acquired by Cubist Pharmaceuticals in 1997, which following U.S. Food and Drug Administration (FDA) approval in September 2003 began marketing the drug under the trade name CUBICIN . Cubicin is marketed in the EU and several other countries by Novartis following its purchase of Chiron Corporation, previous licensee.
Read more about this topic: Daptomycin
Famous quotes containing the word history:
“Those who weep for the happy periods which they encounter in history acknowledge what they want; not the alleviation but the silencing of misery.”
—Albert Camus (1913–1960)
“The greatest honor history can bestow is that of peacemaker.”
—Richard M. Nixon (1913–1995)
“Certainly there is not the fight recorded in Concord history, at least, if in the history of America, that will bear a moment’s comparison with this, whether for the numbers engaged in it, or for the patriotism and heroism displayed.”
—Henry David Thoreau (1817–1862)